Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007924 · ClinicalTrials.gov registry record · Phase 2
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
A Phase 2 study of Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT06007924: Recruiting Phase 2 study of Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06007924 is a Phase 2 study of Thyroid Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06007924, a Phase 2 study of Thyroid Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects.
Primary Outcome
Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
Conditions Studied
Interventions
- DRUG Avutometinib
- DRUG Defactinib
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2027-08-16 |
| Phase | Phase 2 |
What NCT06007924 shows while recruiting
NCT06007924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Avutometinib is the first listed.
NCT06007924 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06007924 about?
NCT06007924 is a clinical study titled "A Study of Avutometinib and Defactinib in People With Thyroid Cancer". The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a...
What is the current status of trial NCT06007924?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-08-16. Estimated completion is 2027-08-16.
What conditions does trial NCT06007924 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT06007924?
The interventions under investigation include: Avutometinib (DRUG), Defactinib (DRUG).
Who is sponsoring clinical trial NCT06007924?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06007924 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06007924's enrollment target sits among peer trials
30 32nd of 46 higher than 13 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
-
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI